Keywords

Cervical Cancer, ASCCP Guidelines, HPV Testing, Self-Collection, At-Home Testing, Women's Health, Diagnostic Solutions, Preventive Care, Medical Technology, Health Access

Summary

In this episode of Clinical Lab Chat, Chris Wolski and Dr. Jeff Andrews discuss significant advancements in cervical cancer prevention, focusing on the new ASCCP guidelines, the role of technology in screening, and the importance of self-collection methods. They explore how these changes can improve access to care for women and the future of at-home testing, while also addressing the psychological barriers and stigmas associated with cervical cancer screening.

Takeaways

• The ASCCP guidelines are essential for managing cervical cancer risk.
• Technology has transformed how guidelines are updated and accessed.
• Self-collection methods can significantly increase screening rates.
• At-home testing is preferred by many women for convenience and privacy.
• Addressing stigmas is crucial for increasing testing participation.
• Cervical cancer is highly treatable when detected early.
• The Onclarity assay provides extended genotyping for better risk assessment.
• Guidelines are now more dynamic and can be updated quickly.
• Improving access to care is vital for women's health.
• The fight against cervical cancer is entering an exciting new phase.

Titles

• Revolutionizing Cervical Cancer Prevention
• The Future of Women's Health Screening

Sound Bites

• "We can update guidelines very quickly now."
• "The app makes it much more dynamic and useful."
• "We're dealing with a couple of stigmas."

Chapters

00:00
Introduction to New Diagnostic Guidelines

02:51
Understanding ASCCP Guidelines and Their Evolution

05:30
The Role of Technology in Women's Health Testing

08:11
Onclarity HPV Assay and Its Significance

10:48
Self-Collection Methods for Cervical Cancer Screening

13:19
The Future of At-Home Testing

15:53
Impact of New Guidelines on Labs and Testing

18:32
Addressing Stigmas and Psychological Barriers

20:45
Conclusion and Future Directions

21:41
Podcast Music Outro.wav

In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion.

Among the topics they discuss:

• The critical importance of making accurate diagnoses of neurodegenerative diseases
• Why alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’s
• How adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregivers
• Why we’re entering a neurological healthcare “golden age”

In this episode of Clinical Lab Chat, CLP Director of Business Intelligence Chris Wolski engages in a wide-ranging discussion with Peggy Lillis Foundation CEO and founder Christian Lillis about the organization’s efforts to raise awareness of C diff. Among the topics they discuss:

• Why C diff is difficult to diagnose
• How Peggy Lillis is engaging with the public, scientific community, and legislators to improve understanding, diagnostics, and treatment of this increasingly common disease
• The parallels of these awareness efforts with other public health education efforts
• How laboratorians can help their organizations develop workflows to avoid under- and over-testing for C diff.